Clinical trials: Emphysema
Chronic Obstructive Pulmonary Disease, Bronchitis
Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate and compare the efficacy of arformoterol twice a day and tiotropium once a day (dosed sequentially) versus tiotropium once a day alone in subjects with Chronic Obstructive Pulmonary…
- Conditions
- Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema
- Trial name
- NCT00424528
- Testing
- Arformoterol Tartrate Inhalation Solution, Tiotropium, Arformoterol and Tiotropium
- Where
- 28 sites in United States
- Volunteers
- 235 people
- Sponsor
- Sumitomo Pharma America, Inc.
Alpha 1-Antitrypsin Deficiency
Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)
The purpose of AROAAT2001 (SEQUOIA) is to evaluate the safety, efficacy and tolerability of multiple doses of the investigational product, Fazirsiran Injection, administered subcutaneously to participants with alpha-1 antitrypsin…
- Trial name
- SEQUOIA (NCT03945292)
- Testing
- Fazisiran Injection
- Where
- 21 sites in United States, Germany and 4 more
- Volunteers
- 40 people
- Sponsor
- Arrowhead Pharmaceuticals
Alpha 1-Antitrypsin Deficiency
Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype
This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-814 in PiZZ subjects.
- Trial name
- NCT04167345
- Testing
- VX-814
- Where
- 28 sites in United States, Canada and 2 more
- Volunteers
- 48 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Pulmonary Disease, Chronic Obstructive
GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease
The study will evaluate the dose response, safety, and pharmacokinetics of GSK573719 compared with placebo in subjects with COPD.
- Trial name
- NCT00950807
- Testing
- Tiotropium, GSK573179
- Where
- 19 sites in United States, Germany
- Volunteers
- 176 people
- Sponsor
- GlaxoSmithKline
Emphysema, Alpha 1-proteinase Inhibitor Deficiency
Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.
This study is a continuation of the placebo-controlled study CE1226_4001 (NCT00261833) to evaluate the efficacy and safety of Zemaira® intravenous (i.v).
- Trial name
- NCT00670007
- Testing
- Alpha1- proteinase inhibitor [human]
- Where
- 21 sites in Australia, Canada and 9 more
- Volunteers
- 140 people
- Sponsor
- CSL Behring
COPD, Emphysema
Implementing and Evaluating the Genie Tool in COPD
The Generating Engagement in Network Involvement (GENIE) Tool is designed to support people to find and join social activities in their own neighbourhoods.
- Trial name
- GeCop (NCT02935452)
- Testing
- GENIE - social networking tool
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University of Southampton
Chronic Obstructive Pulmonary Disease
Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD)
Chronic obstructive pulmonary disease (COPD) is a progressive disorder of the lung parenchyma and airways, which is the third-leading cause of death in the USA.
- Trial name
- Quercetin (NCT01708278)
- Testing
- Quercetin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Michigan
Smoking, HIV Infections
Smoking Cessation Using Motivational Therapy and Varenicline
People that are infected with HIV appear to be especially susceptible to the adverse effects of cigarette smoking. The purpose of this study is to determine if quitting smoking by using a specialized smoking cessation treatment…
- Trial name
- NCT00701896
- Testing
- Varenicline tartrate, Nicotine Replacement Therapy, Biological Control
- Where
- United States
- Volunteers
- 294 people
- Sponsor
- Philip Diaz
Alpha 1-Antitrypsin Deficiency
Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)
The purpose of this study is to evaluate the the safety and efficacy of the investigational product, fazirsiran (TAK-999, ARO-AAT), administered subcutaneously to patients with alpha-1 antitrypsin deficiency associated liver…
- Trial name
- NCT03946449
- Testing
- ARO-AAT
- Where
- 4 sites in Austria, Germany and 1 more
- Volunteers
- 16 people
- Sponsor
- Arrowhead Pharmaceuticals
COPD
Effects of Roflumilast in Hospitalized Chronic Obstructive Pulmonary Disease( COPD) on Mortality and Re-hospitalization
Background: COPD exacerbations add considerably to patients' burden because they: (1) cause frequent hospital admissions and relapses or readmissions, (2) contribute directly to the death of many patients, either during…
- Trial name
- NCT01973998
- Testing
- Roflumilast
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Temple University
COPD, Emphysema
Mechanistic Effects of Health Coaching to Reduce Chronic Obstructive Pulmonary Disease (COPD) Hospitalizations
The researchers are trying to explore the benefit of Health Coaching on patients with severe symptoms of COPD.
- Trial name
- NCT03837847
- Testing
- Health Coaching Calls, Control
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Mayo Clinic
Emphysema
Pulmonx Endobronchial Valves Used in Treatment of Emphysema (LIBERATE Study)
The purpose of this research is to study an investigational medical device that is designed to produce lung volume reduction in diseased areas of the lungs in patients with severe emphysema.
- Trial name
- LIBERATE (NCT01796392)
- Testing
- EBV, Optimal Medical Management
- Where
- 23 sites in United States, Brazil and 2 more
- Volunteers
- 190 people
- Sponsor
- Pulmonx Corporation
Pulmonary Hypertension, Interstitial Lung Disease
Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
This was a multicenter, randomized (1:1 inhaled treprostinil: placebo), double-blinded, placebo-controlled trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension…
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
- Trial name
- NCT02630316
- Testing
- Inhaled Treprostinil
- Where
- 97 sites in United States, Puerto Rico
- Volunteers
- 326 people
- Sponsor
- United Therapeutics
Chronic Obstructive Pulmonary Disease
Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
The purpose of this study is to assess the long-term safety and tolerability of inhaled aclidinium bromide/formoterol in patients with moderate to severe, stable chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01437540
- Testing
- Aclidinium Bromide/Formoterol Fumarate, Formoterol Fumarate
- Where
- 137 sites in United States
- Volunteers
- 590 people
- Sponsor
- AstraZeneca
Pulmonary Disease, COPD
Improving the Quality of End-of-Life Communication for Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate a multifaceted intervention to improve the quality of end-of-life communication between patients with COPD and their primary care providers using information about patients preferences for…
- Conditions
- Pulmonary Disease, COPD, Chronic Bronchitis, Emphysema
- Trial name
- NCT00106080
- Testing
- Audit and Feedback
- Where
- United States
- Volunteers
- 376 people
- Sponsor
- VA Office of Research and Development
COPD, Chronic Bronchitis
The Effectiveness of Roflumilast in Improving Mucociliary Clearance in Patients With COPD and Chronic Bronchitis
Specific Aim: To determine the effectiveness of Roflumilast in improving i) whole right lung and ii) peripheral right lung mucociliary clearance (MCC) in patients with COPD and chronic bronchitis.
- Conditions
- COPD, Chronic Bronchitis, Emphysema
- Trial name
- NCT03073798
- Testing
- Roflumilast
- Volunteers
- 12 people
- Sponsor
- Johns Hopkins University
Alpha 1-Antitrypsin Deficiency
A Study of Belcesiran in Patients With AATLD
This is a multiple dose, randomized, placebo-controlled, double-blind study of belcesiran to evaluate the safety, tolerability, PK, and PD in adult patients with PiZZ AATD-associated liver disease (AATLD).
- Trial name
- ESTRELLA (NCT04764448)
- Testing
- Belcesiran
- Where
- 23 sites in United States, Australia and 12 more
- Volunteers
- 16 people
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Pulmonary Disease, Chronic Obstructive
28-day Repeat Dose Study of GSK573719
The study will evaluate the efficacy, safety, and pharmacokinetics of GSK573719 compared with placebo in subjects with COPD
- Trial name
- NCT01030965
- Testing
- GSK573719 125mcg, GSK573719 250mcg, GSK573719 500mcg
- Where
- 20 sites in United States, Estonia and 2 more
- Volunteers
- 285 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema
Phase 2a multicenter, randomized, double-blind, placebo-controlled study to assess the pharmacodynamics, efficacy, and safety of tetomilast in patients with emphysema.
- Trial name
- EMPHASIS (NCT00874497)
- Testing
- tetomilast
- Where
- 15 sites in United States
- Volunteers
- 84 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Chronic Obstructive Pulmonary Disease, Alpha1-antitrypsin Deficiency
Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency
The purpose of this study is to conduct a pilot study to evaluate the safety and efficacy of weekly administration of Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy in subjects with A1PI deficiency and emphysema/ chronic…
- Trial name
- NCT02722304
- Testing
- ARALAST NP 60 mg/kg, ARALAST NP 120 mg/kg, GLASSIA 60 mg/kg
- Where
- 17 sites in United States, Australia and 1 more
- Volunteers
- 7 people
- Sponsor
- Baxalta now part of Shire